Neuropsychological Outcomes of Gender-Affirming Hormone Therapy: Advancing Inclusive Mental Health, Cognitive Function and Psychosocial Well-Being
Journal of Pioneering Medical Sciences · 05.06.2026 · 15 (05) · 123-143
DOI: 10.47310/jpms2026150517 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pioneering Medical Sciences, online erschienen am 05.06.2026. Verfasst von Bhoopathi Reddy und 7 weiteren Autor:innen.
Abstract (Originalsprache)
Gender-Affirming Hormone Therapy (GAHT), commonly referred to as cross-sex hormone therapy (CSHT), represents an essential healthcare intervention that supports individuals in achieving congruence between their physical characteristics and gender identity. Access to such affirming medical care contributes to improved mental health outcomes, psychosocial stability and overall quality of life, particularly among gender-diverse populations who often experience disparities in health and well-being. This study aims to review and analyse the neuropsychological outcomes of CSHT, focusing on cognitive, emotional and behavioural domains among transgender individuals. The primary objective is to examine how hormone-based interventions influence cognitive functioning, emotional regulation and behavioural adaptation, while contributing to improved psychological resilience and social participation. Data for this research were collected through a mixed-method approach, including primary data from questionnaires administered to 406 participants and secondary data derived from previously published scholarly literature on related topics. The findings indicate that testosterone therapy in transgender men may enhance visuospatial abilities and increase energy levels, whereas estrogen therapy in transgender women may promote heightened emotional responsiveness while potentially influencing certain spatial skills. Emotional outcomes largely demonstrate reductions in gender dysphoria, anxiety and depressive symptoms, along with improvements in self-esteem and social functioning. Behaviourally, individuals undergoing CSHT often report increased confidence, improved interpersonal engagement and greater adaptability in social environments, although variations in libido and aggression remain individualized. Neuroimaging evidence from existing studies further suggests structural brain changes that increasingly align with affirmed gender identity. In conclusion, CSHT contributes to meaningful neuropsychological changes that support enhanced mental health, emotional well-being and social inclusion. These findings highlight the importance of equitable access to gender-affirming healthcare and the need for continued longitudinal research and interdisciplinary, patient-centred care approaches to address individual variability and promote sustainable health outcomes across diverse populations.
Zitieren
APA
Reddy, B., Murugadoss, H., Murugadoss, H. D., Shireen, E. F., Devi, M. N., Fletcher, H. J., Priya, N. D. S., & Sivany, B. (2026). Neuropsychological Outcomes of Gender-Affirming Hormone Therapy: Advancing Inclusive Mental Health, Cognitive Function and Psychosocial Well-Being. Journal of Pioneering Medical Sciences, 15(05), 123-143. https://doi.org/10.47310/jpms2026150517
Vancouver
Reddy B, Murugadoss H, Murugadoss HD, Shireen EF, Devi MN, Fletcher HJ, et al. Neuropsychological Outcomes of Gender-Affirming Hormone Therapy: Advancing Inclusive Mental Health, Cognitive Function and Psychosocial Well-Being. Journal of Pioneering Medical Sciences. 2026;15(05):123-143. doi:10.47310/jpms2026150517
BibTeX
@article{Reddy2026,
author = {Reddy, Bhoopathi and Murugadoss, Harihashini and Murugadoss, Hari Dharshini and Shireen, E.S. Felyshia and Devi, M. Nandhini and Fletcher, Herschelle John and Priya, N.S. Devi Shakthi and Sivany, B.},
title = {Neuropsychological Outcomes of Gender-Affirming Hormone Therapy: Advancing Inclusive Mental Health, Cognitive Function and Psychosocial Well-Being},
journal = {Journal of Pioneering Medical Sciences},
year = {2026},
volume = {15},
number = {05},
pages = {123--143},
doi = {10.47310/jpms2026150517}
}
EUVIMED